Vaxart Past Earnings Performance

Past criteria checks 0/6

Vaxart's earnings have been declining at an average annual rate of -25.9%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 10.1% per year.

Key information

-25.9%

Earnings growth rate

5.6%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate10.1%
Return on equity-105.7%
Net Margin-431.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

Nov 16
Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Aug 20
There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Jun 15
An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Nov 08
Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Jun 30
Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis

Sep 09

Ray Stapleton joins Vaxart as CTO

Aug 31

Vaxart shareholders approve proposal to increase number of shares

Aug 05

Vaxart continues to lobby shareholders to vote to increase number of shares

Jul 29

Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2

Jul 20

Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success

Jul 07

Vaxart: A Unique Vaccine Concern

Jun 14

Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform

Feb 26

Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow

Dec 09

Vaxart: Differentiated Covid Oral Route Remains Viable

Nov 16

Vaxart: A Close Look At Their COVID-19 Oral Tablet Vaccine Program

Oct 30

Revenue & Expenses Breakdown

How Vaxart makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:VXRT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2417-7222-2
30 Jun 2414-76230
31 Mar 249-82230
31 Dec 237-82230
30 Sep 234-89240
30 Jun 232-101260
31 Mar 231-108290
31 Dec 220-108290
30 Sep 220-105290
30 Jun 220-93270
31 Mar 220-80230
31 Dec 211-70220
30 Sep 211-64210
30 Jun 211-54200
31 Mar 212-47190
31 Dec 204-32150
30 Sep 208-25110
30 Jun 208-2290
31 Mar 207-1960
31 Dec 1910-1960
30 Sep 198-1760
30 Jun 198-1860
31 Mar 198-2270
31 Dec 184-1870
30 Sep 183-1560
30 Jun 184-1250
31 Mar 185-730
31 Dec 176-1230
30 Sep 179-1630
31 Dec 168-1930
31 Dec 150-2230

Quality Earnings: VXRT is currently unprofitable.

Growing Profit Margin: VXRT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: VXRT is unprofitable, and losses have increased over the past 5 years at a rate of 25.9% per year.

Accelerating Growth: Unable to compare VXRT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VXRT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: VXRT has a negative Return on Equity (-105.69%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies